Do patients with small ER+ tumors with high genomic risk benefit from chemotherapy?
An article by Florentine Hilbers, Postdoctoral Researcher at The Netherlands Cancer Institute, was recently mentioned by Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, on X:
“Do patients with small (≤1cm) ER+ tumors with high genomic risk benefit from chemotherapy?
Interesting analysis of MINDACT: favorable outcomes (93% 8y DMFS) and no clear benefit from chemotherapy despite high genomic risk. Think twice before giving chemo for T1a/b ER+ tumors.”
Authors: Florentine Hilbers, Coralie Poncet, Konstantinos Tryfonidis, Giuseppe Viale, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Isabel Rubio, Alastair Thompson, Emiel Rutgers, Martine Piccart, Laura van ’t Veer and Fatima Cardoso.
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023